Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Summary

This phase II trial is studying how well brivanib alaninate works in treating patients with endometrial cancer that has come back (recurred) or is persistent. Brivanib alaninate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Timeline

Start

2009-07-06

Primary completion

2016-07-16

Completion

2016-07-16

Drugs

Indications